Investor Relations

Print page     Email page

Myriad Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.

Recent Releases Feb 3, 2010 Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th Feb 2, 2010 FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM) View all releases » Events & Presentations Feb 16, 2010 17th Conference on Retroviruses and Opportunistic Infections (CROI 2010) Apr 17, 2010 AACR 101st Annual Meeting View all events & presentations »

Stock Chart 3 Mo.   6 Mo.   1 Yr. Stock Quote Myriad Pharmaceuticals, Inc. Price: 4.20 Change: -0.07 Day High: 4.28 Day Low: 4.20 Volume: 111,700 Delayed at least 20 minutes. Provided by eSignal.